缺血预适应对失血性休克大鼠的保护作用研究  

Beneficial effects of ischemia preconditioning on hemorrhagic shock rats

作　　者：徐竞[1] 蓝丹[1] 李涛[1] 杨光明[1] 刘良明[1] 

机构地区：[1]第三军医大学大坪医院野战外科研究所第二研究室创伤,烧伤与复合伤国家重点实验室,重庆400042

出　　处：《创伤外科杂志》2012年第1期56-60,共5页Journal of Traumatic Surgery

基　　金：国家重点基础研究发展计划项目(2005CB522601);国家杰出青年科学基金(30625037)

摘　　要：目的目的观察缺血预适应对失血性休克大鼠的保护作用。方法采用失血性休克复苏大鼠,观察缺血预适应对大鼠存活、血管收缩反应、血流动力学[平均动脉压(MAP)、左室收缩压(LVSP)、左室舒张末压(LVEDP)、左室压最大上升/下降速率(±dp/dtmax)、心率(HR)]、肝肾灌注和线粒体功能的影响。结果缺血预适应可延长失血性休克复苏大鼠存活时间,恢复血管对去甲肾上腺素(NE)和Ca2+的反应性,恢复MAP、LVSP、LVEDP、±dp/dtmax、HR、NE升压效应,增加肝肾血流量、线粒体呼吸控制率和Na+-K+-三磷酸腺苷(ATP)酶活性(P<0.01)。结论缺血预适应恢复血管收缩反应,改善血流动力学、血流灌注和线粒体功能,从而延长失血性休克复苏大鼠存活时间。Objective To observe the beneficial effects of ischemia preconditioning on hemorrhagic shock rats. Methods Using hemorrhagic shock rats, the animal survival time, vascular reactivity and calcium sensitivity were evaluated. And hemodynamic parameters were observed after isebemia preconditioning and shock-resuscitation including mean arterial blood pressure （MAP） ,left intraventricular systolic pressure （LVSP） ,left ventricular end-di- astolic pressure（ LVEDP）, maximal change rate of left intraventricular pressure （ ＋ dp/dtmax）, heart rate （HR）, blood flow and mitochondrial function of liver and kidney. Results As compared with simple fluid resuscitation,is- chemia preconditioning significantly prolonged the survival time and survival rate of shock-resuscitation rats,increased the vascular contraction to norepinephrine （NE） and Ca2＋, restored the hemodynamic parameters including MAP, LVSP, LVEDP, ＋ dp/dtmax, - dp/dtmax, HR and the pressor effect of NE, increased the blood flow, the mitochondrial respiration control ratio （ RCR ） and Na ＋ -K ＊ -ATP activity of liver and kidney （ P 〈 O. 01 ）. Conclusion Ischemia preconditioning prolonged the animal survival time of hemorrhagic shock rats through increasing the vascular reactivity and calcium sensitivity and improving hemodynamics,blood flow and mitochondrial function of vital organs.

关 键 词：失血性休克 缺血预适应 血流动力学 血流灌注 线粒体 

分 类 号：R363[医药卫生—病理学] R605.971[医药卫生—基础医学]